Brief: Relmada Therapeutics Expects To Report Top-Line Data From Reliance III Trial Early Next Quarter

Relmada Therapeutics

20/09/2022 14:33

Sept 20 (Reuters) - Relmada Therapeutics Inc  RLMD.O :
    * RELMADA THERAPEUTICS ANNOUNCES COMPLETION OF TREATMENT IN
COMPANY'S REGISTRATIONAL PHASE 3 RELIANCE III TRIAL FOR REL-1017
AS A MONOTHERAPY FOR MAJOR DEPRESSIVE DISORDER
    * RELMADA THERAPEUTICS ANNOUNCES COMPLETION OF TREATMENT IN
COMPANY'S REGISTRATIONAL PHASE 3 RELIANCE III TRIAL FOR REL-1017
AS A MONOTHERAPY FOR MAJOR DEPRESSIVE DISORDER
    * RELMADA THERAPEUTICS INC - EXPECTS TO REPORT TOP-LINE DATA
FROM
RELIANCE III TRIAL EARLY NEXT QUARTER

Source text for Eikon:  ID:nPn2bHSY8a 
Further company coverage:  RLMD.O 

 ((Reuters.Briefs@thomsonreuters.com;))